Fragile X Syndrome Pipeline Assessment | Insights into the Current Therapies, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook | Key Companies - Anavex (ANAVEX2-73/blarcamesine), Zynerba, Autifony, Marinus, Healx

As per DelveInsight's assessment, globally, about 20+ key pharma and biotech companies are working on 22+ pipeline drugs in the Fragile X Syndrome therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA) and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Fragile X Syndrome Pipeline Insight, 2022" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Fragile X Syndrome Therapeutics Market.

The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).

The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Fragile X Syndrome Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Fragile X Syndrome Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Fragile X Syndrome treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Fragile X Syndrome market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

DelveInsight's Report covers around 22+ products under different phases of clinical development like -
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage products (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/report-store/fragile-x-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Some of the key companies in the Fragile X Syndrome Market include:
• Zynerba Pharmaceuticals
• Tetra Therapeutics
• Autifony Therapeutics
• Prilenia Therapeutics
• Alcobra Ltd.
• Seaside Therapeutics, Inc.
• Marinus Pharmaceuticals
• Novartis Pharmaceuticals
• Neuren Pharmaceuticals
• Hoffmann-La Roche
• Healx
• Nova Mentis
• Lysogene
• Actinogen
• Prilenia Therapeutics
• Confluence Pharmaceuticals
• Sentinel Oncology
And many more

Fragile X Syndrome Drugs covered in the report include
• Zatolmilast: Tetra Discovery Partners
• Zygel: Zynerba Pharmaceuticals
• Pridopidine: Prilenia Therapeutics
And many others

Download Sample Pages to Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/fragile-x-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Content
1. Report Introduction
2. Executive Summary
3. Fragile X Syndrome Current Treatment Patterns
4. Fragile X Syndrome - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Fragile X Syndrome Late Stage Products (Phase-III)
7. Fragile X Syndrome Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Fragile X Syndrome Discontinued Products
13. Fragile X Syndrome Product Profiles
14. Fragile X Syndrome Key Companies
15. Fragile X Syndrome Key Products
16. Dormant and Discontinued Products
17. Fragile X Syndrome Unmet Needs
18. Fragile X Syndrome Future Perspectives
19. Fragile X Syndrome Analyst Review
20. Appendix
21. Report Methodology
*The table of contents is not exhaustive; the final content may vary.

Request the Sample PDF to Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/fragile-x-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/fragile-x-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.